Clopidogrel

Coadministration not recommended due to increased bupropion exposure and decreased hydroxybupropion exposure.

Coadministration not recommended due to increased bupropion exposure and decreased hydroxybupropion exposure.

Do not administer during cangrelor infusion. Clopidogrel will have no antiplatelet effect until the next dose is administered after cangrelor infusion is discontinued.

Esomeprazole 40 mg reduces plasma concentrations of clopidogrel's active metabolite and platelet inhibition. Concomitant use is contraindicated.

Clopidogrel increases repaglinide exposure by 3.9- to 5.1-fold. Avoid concomitant use.

Antiplatelet agent that increases bleeding risk when coadministered with apixaban. Dual antiplatelet therapy with apixaban resulted in 5.9% major bleeding per year versus 2.5% with placebo.

Moderate CYP2C8 inhibitor increasing daprodustat exposure. Requires dose reduction by half and hemoglobin monitoring.

Omeprazole or Esomeprazole Avoid concomitant use of clopidogrel with omeprazole or esomeprazole. A similar reduction in antiplatelet activity was observed with esomeprazole when given concomitantly with clopidogrel. Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of clopidogrel than did omeprazole or esomeprazole [ see Warnings and Precautions ( 5.1 ) and Clinical Pharmacology ( 12.3 ) ].

Concomitant use of esomeprazole 40 mg reduced plasma concentrations of active metabolite of clopidogrel and platelet inhibition.

Concomitant use of esomeprazole 40 mg reduced plasma concentrations of the active metabolite and platelet inhibition.

Concomitant use of esomeprazole 40 mg resulted in reduced plasma concentrations of the active metabolite and a reduction in platelet inhibition.

Pyridoxine interaction with Clopidogrel may increase bleeding risk.

Possibility of increased bleeding due to pyridoxine interaction with anticoagulants.

Possibility of increased bleeding due to pyridoxine interaction with anticoagulants.

Possibility of increased bleeding due to folic acid interaction with anticoagulants.

NSAID co-administration with clopidogrel increases risk of gastrointestinal bleeding.

Opioid agonist delays and reduces clopidogrel absorption, decreasing exposure to metabolites. Consider parenteral antiplatelet agent in acute coronary syndrome.

Pyridoxine in the multivitamin may increase bleeding risk when used with anticoagulants.

Coadministration increases the risk of gastrointestinal bleeding.

Coadministration increases risk of gastrointestinal bleeding.

Omeprazole or Esomeprazole Avoid concomitant use of clopidogrel with omeprazole or esomeprazole. In clinical studies, omeprazole was shown to reduce significantly the antiplatelet activity of clopidogrel when given concomitantly or 12 hours apart. A similar reduction in antiplatelet activity was observed with esomeprazole when given concomitantly with clopidogrel.

Omeprazole 80 mg reduces plasma concentrations of clopidogrel's active metabolite and reduces platelet inhibition.

Omeprazole 80 mg results in reduced plasma concentrations of clopidogrel's active metabolite and reduced platelet inhibition.

CYP2C19 substrate with increased plasma concentrations when combined with omeprazole. Avoid concomitant use; consider alternative anti-platelet therapy.

Concurrent use of clopidogrel with paroxetine may potentiate the risk of bleeding.

Increased bleeding risk when combined with paroxetine. Inform patients of increased bleeding risk.

Increased risk of bleeding with concurrent use; inform patients of increased bleeding risk.

Moderate CYP2C8 inhibitor; reduce REZDIFFRA dosage as it increases resmetirom Cmax and AUC, increasing risk of adverse reactions.

Strong CYP2C19 inducer increases clopidogrel active metabolite levels and platelet inhibition, potentiating risk of bleeding. Avoid concomitant use.

Platelet aggregation inhibitor coadministration may increase bleeding risk. Promptly evaluate signs/symptoms of blood loss.

SSRIs affect platelet activation and concomitant use with clopidogrel may increase the risk of bleeding.

Concurrent use may potentiate bleeding risk. Inform patients of increased bleeding risk.

Concurrent use may potentiate risk of bleeding.

Increased risk of bleeding due to serotonin effects on platelet hemostasis with antiplatelet agent use.

Vonoprazan is a CYP2C19 inhibitor and may reduce plasma concentrations of clopidogrel's active metabolite, reducing platelet inhibition.

Coadministration increases bleeding risk due to independent effects on hemostasis, despite no pharmacokinetic interaction.

CYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.

CYP2B6 inhibitor that increases bupropion exposure and decreases hydroxybupropion exposure. Dosage adjustment of bupropion may be necessary based on clinical response.

CYP2B6 inhibitor that can increase bupropion exposure while decreasing hydroxybupropion exposure. Dosage adjustment may be necessary based on clinical response.

CYP2C19 inhibitor with less effect on clopidogrel antiplatelet activity compared to omeprazole or esomeprazole.

CYP2C19 inhibitor with less effect on clopidogrel antiplatelet activity compared to omeprazole or esomeprazole.

CYP2B6 inhibitor that can increase bupropion exposure. Do not exceed one tablet twice daily when taken with clopidogrel.

CYP2C19 inhibitor with less effect on clopidogrel antiplatelet activity compared to omeprazole or esomeprazole.

Doses up to 75 mg daily were allowed in clinical studies. Consider risks and benefits of concomitant antithrombotic use.

Moderate CYP2C8 inhibitor that increased active metabolite exposure approximately 2.7-fold. Reduce selexipag dosing to once daily.

DIACOMIT may inhibit CYP2C19 metabolism of clopidogrel; consider dose reduction if adverse reactions occur.

Concomitant administration had no clinically important effect on exposure to active metabolite or clopidogrel-induced platelet inhibition.

Concomitant administration of pantoprazole and clopidogrel had no clinically important effect on exposure to active metabolite or platelet inhibition.

Concomitant administration of pantoprazole and clopidogrel had no clinically important effect on exposure to active metabolite or platelet inhibition.